奈玛特韦片与阿兹夫定区别？

The difference between Nematvir tablets and Azivudine

Nematvir tablets and Azivudine can both treat COVID-19 infection, but there are differences between the two drugs. (Paxlovid (nematvir + ritonavir)) and Azivudine are different in terms of indications, usage and dosage, side effects, therapeutic effects and mechanism of action.

Nematvir tablets and Azivudine have different indications

Paxlovid (nematvir + ritonavir) is used to treat confirmed COVID-19 patients with mild to moderate symptoms and high risk factors for progression to severe disease. These patients must be 12 years old and above and weigh at least 40 kilograms. The indications for Azivudine treatment are adult patients aged 18 and above with common COVID-19 (new coronavirus infection).

The recommended dosage of Paxlovid (nematvir + ritonavir) is: nematvir 300mg (2 tablets) + ritonavir 100mg (1 tablet), taken orally every 12 hours, that is, twice a day. Patients with moderate renal impairment: Nematvir 1 50 mg (1 tablet) + ritonavir 100 mg (1 tablet), taken orally every 12 hours. Continue taking the medicine for 5 days. Take within 5 days of symptoms onset. Paxlovid (nematvir + ritonavir) can be taken by mouth before or after meals. Swallow the tablet whole and do not break, chew or crush it.

The recommended usage and dosage of Azivudine is 5 mg each time, once a day, for 5 days, no more than 14 days, and within 5 days after the onset of symptoms. It needs to be taken on an empty stomach. To ensure the dosage, the tablet should be swallowed whole and cannot be crushed. Use with caution in patients with moderate to severe liver damage.

Nematvir tablets and Azivudine have different side effects

Paxlovid (nematvir + ritonavir) mainly causes taste changes (bitter taste), diarrhea, indigestion, gastroesophageal reflux disease, vomiting, and muscle aches. The common side effects of Azivudine are fever, dizziness, nausea, and diarrhea.

According to US FDA data: Paxlovid (nematvir + ritonavir) reduces the risk of hospitalization and death in high-risk patients with severe disease by 88%. The domestic trial results of Azivudine showed that 40.43% of clinical symptoms were improved and the viral load decreased on the 5th day.

Nematvir tablets and Azivudine have different mechanisms of action

Paxlovid (nematvir + ritonavir) prevents the virus that causes COVID-19 from replicating itself. Viruses rely on enzymes (proteins) in the human body called proteases to make copies of themselves. Nematvir temporarily stops this enzyme from working so the virus cannot use it to reproduce. Ritonavir: Ritonavir essentially shuts down the metabolism of nematvir in the liver so that nematvir is not eliminated from your body as quickly, which means that nematvir can work longer to increase its effectiveness in helping to fight viral infections.

Azivudine embeds the viral RNA during the synthesis process of the new coronavirus RNA, thereby inhibiting the replication of the new coronavirus and achieving the effect of treating the new coronavirus infection.

Nematvir tablets Paxlovid (nematvir + ritonavir) are developed and produced by Pfizer, and were approved for marketing by the US FDA emergency use authorization on December 22, 2021. Azivudine is developed and produced by real biological companies in China, and was conditionally approved for marketing by the State Food and Drug Administration of China on July 25, 2022. It is recommended that patients choose the appropriate version according to their own conditions under the guidance of a doctor. If they need Paxlovid (nematvir + ritonavir), they can consult customer service personnel to obtain guaranteed overseas drugs and sign a drug protection contract.

Recommended related articles: